Danuglipron Tracker
Track Pfizer's Once-Daily Oral GLP-1 Pill
Danuglipron is Pfizer's oral small-molecule GLP-1 receptor agonist in development. No injections, no fasting requirements. Track your doses, weight, and side effects with Shotlee as the drug progresses toward approval.
What is Danuglipron?
Danuglipron is Pfizer's oral small-molecule GLP-1 receptor agonist. It is a non-peptide molecule that can be taken as a standard tablet without special fasting requirements — unlike Rybelsus, which requires 30-minute fasting before food.
An earlier twice-daily formulation was discontinued due to elevated liver enzyme levels and GI tolerability concerns in some patients. Pfizer is now advancing a once-daily formulation with an improved safety profile. Phase 2 data from the twice-daily study showed significant HbA1c reduction and weight loss, demonstrating the molecule's fundamental efficacy.
Danuglipron remains behind Eli Lilly's orforglipron in the race for oral GLP-1 approval. However, if successful, Pfizer's manufacturing scale and distribution network could make danuglipron a significant option in the oral GLP-1 market.
FAQ
What is danuglipron?
Pfizer's once-daily oral GLP-1 receptor agonist in clinical development. No injections or fasting required. Phase 2 showed meaningful blood sugar reduction and weight loss. An improved once-daily formulation is under assessment as of 2026.
Is danuglipron approved?
Not yet. Pfizer is developing an improved once-daily formulation after the twice-daily version was discontinued. Clinical development is ongoing.
How does it compare to orforglipron?
Orforglipron (Eli Lilly) is ahead in development with Phase 3 data and an expected mid-2026 FDA decision. Danuglipron is behind but represents Pfizer's entry into the oral GLP-1 space.